Security key
67080M103
Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (NRIX)
CUSIP: 67080M103
Q4 2024 13F Holders as of 31 Dec 2024
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Shares outstanding
- 103,174,603
- Total 13F shares
- 81,104,522
- Share change
- +12,417,893
- Total reported value
- $1,528,053,172
- Put/Call ratio
- 13%
- Price per share
- $18.84
- Number of holders
- 173
- Value change
- +$225,677,197
- Number of buys
- 91
- Number of sells
- 76
Report period
Q4 2024
Institutions
173
Top holders
10
NRIX full security history
Newer quarter: Q1 2025
Previous quarter: Q3 2024
Nurix Therapeutics, Inc. SEC filings
Nurix Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 67080M103
Recent filing periods:
Top shareholders of NRIX - Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. |
13F
|
Company |
7%
|
7,181,535
|
$161,369,093 | — | 30 Sep 2024 | |
| Redmile Group, LLC |
13F
|
Company |
4.1%
|
4,280,981
|
$96,193,643 | — | 30 Sep 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
3.9%
|
4,011,814
|
$90,145,461 | — | 30 Sep 2024 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
3.8%
|
3,882,125
|
$87,231,349 | — | 30 Sep 2024 | |
| Deep Track Capital, LP |
13F
|
Company |
3.7%
|
3,868,104
|
$86,916,297 | — | 30 Sep 2024 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
3.4%
|
3,482,105
|
$78,242,898 | — | 30 Sep 2024 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
3%
|
3,068,961
|
$68,961,000 | — | 30 Sep 2024 | |
| T. Rowe Price Investment Management, Inc. |
13F
|
Company |
2.5%
|
2,548,091
|
$57,256,000 | — | 30 Sep 2024 | |
| STATE STREET CORP |
13F
|
Company |
2.3%
|
2,371,271
|
$53,282,459 | — | 30 Sep 2024 | |
| ARK Investment Management LLC |
13F
|
Company |
2.1%
|
2,216,365
|
$49,801,724 | — | 30 Sep 2024 | |
| MORGAN STANLEY |
13F
|
Company |
1.8%
|
1,878,564
|
$42,211,334 | — | 30 Sep 2024 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
1.7%
|
1,788,530
|
$40,188,269 | — | 30 Sep 2024 | |
| Commodore Capital LP |
13F
|
Company |
1.6%
|
1,650,000
|
$37,075,500 | — | 30 Sep 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
1.5%
|
1,531,205
|
$34,406,177 | — | 30 Sep 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.4%
|
1,448,040
|
$32,543,817 | — | 30 Sep 2024 | |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
|
Company |
1.2%
|
1,285,632
|
$28,888,151 | — | 30 Sep 2024 | |
| Soleus Capital Management, L.P. |
13F
|
Company |
1%
|
1,065,834
|
$23,949,290 | — | 30 Sep 2024 | |
| S.c.a. Candriam |
13F
|
Individual |
1%
|
1,061,959
|
$23,861,149 | — | 30 Sep 2024 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
0.83%
|
860,399
|
$19,333,166 | — | 30 Sep 2024 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.83%
|
854,682
|
$19,204,704 | — | 30 Sep 2024 | |
| WASATCH ADVISORS LP |
13F
|
Company |
0.69%
|
708,377
|
$15,917,231 | — | 30 Sep 2024 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
0.65%
|
673,554
|
$15,134,759 | — | 30 Sep 2024 | |
| FMR LLC |
13F
|
Company |
0.57%
|
586,902
|
$13,187,689 | — | 30 Sep 2024 | |
| SAMLYN CAPITAL, LLC |
13F
|
Company |
0.55%
|
568,264
|
$12,768,893 | — | 30 Sep 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.55%
|
566,855
|
$12,737,232 | — | 30 Sep 2024 | |
| Boxer Capital, LLC |
13F
|
Company |
0.55%
|
563,067
|
$12,652,115 | — | 30 Sep 2024 | |
| Sumitomo Mitsui Trust Group, Inc. |
13F
|
Company |
0.54%
|
553,251
|
$12,431,550 | — | 30 Sep 2024 | |
| Amova Asset Management Americas, Inc. |
13F
|
Company |
0.54%
|
552,602
|
$12,405,915 | — | 30 Sep 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.5%
|
513,221
|
$11,532,076 | — | 30 Sep 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.5%
|
511,720
|
$11,498,348 | — | 30 Sep 2024 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.49%
|
501,569
|
$11,271,870 | — | 30 Sep 2024 | |
| Parkman Healthcare Partners LLC |
13F
|
Company |
0.43%
|
438,971
|
$9,863,678 | — | 30 Sep 2024 | |
| Vestal Point Capital, LP |
13F
|
Company |
0.41%
|
425,000
|
$9,549,750 | — | 30 Sep 2024 | |
| Opaleye Management Inc. |
13F
|
Company |
0.41%
|
420,000
|
$9,437,400 | — | 30 Sep 2024 | |
| Invesco Ltd. |
13F
|
Company |
0.4%
|
413,340
|
$9,287,749 | — | 30 Sep 2024 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
0.34%
|
355,602
|
$7,990,376 | — | 30 Sep 2024 | |
| LORD, ABBETT & CO. LLC |
13F
|
Company |
0.34%
|
350,640
|
$7,879,000 | — | 30 Sep 2024 | |
| Woodline Partners LP |
13F
|
Company |
0.33%
|
336,879
|
$7,569,671 | — | 30 Sep 2024 | |
| Patient Square Capital LP |
13F
|
Company |
0.32%
|
325,789
|
$7,320,479 | — | 30 Sep 2024 | |
| NORGES BANK |
13F
|
Company |
0.31%
|
318,800
|
$7,163,436 | — | 30 Sep 2024 | |
| ArrowMark Colorado Holdings LLC |
13F
|
Company |
0.31%
|
314,762
|
$7,072,702 | — | 30 Sep 2024 | |
| BESSEMER GROUP INC |
13F
|
Company |
0.3%
|
306,053
|
$6,877,000 | — | 30 Sep 2024 | |
| Rhenman & Partners Asset Management AB |
13F
|
Company |
0.29%
|
300,000
|
$6,741,000 | — | 30 Sep 2024 | |
| PRIMECAP MANAGEMENT CO/CA/ |
13F
|
Company |
0.28%
|
290,000
|
$6,516,300 | — | 30 Sep 2024 | |
| Ikarian Capital, LLC |
13F
|
Company |
0.25%
|
260,000
|
$5,842,200 | — | 30 Sep 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.24%
|
246,400
|
$5,536,608 | — | 30 Sep 2024 | |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC |
13F
|
Company |
0.23%
|
241,048
|
$5,416,349 | — | 30 Sep 2024 | |
| WestHill Financial Advisors, Inc. |
13F
|
Company |
0.23%
|
238,333
|
$5,355,343 | — | 30 Sep 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.21%
|
221,718
|
$4,982,003 | — | 30 Sep 2024 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.21%
|
214,728
|
$4,824,938 | — | 30 Sep 2024 |
Institutional Holders of Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (NRIX) as of Q4 2024
As of 31 Dec 2024,
Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (NRIX) was held by
173 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
81,104,522 shares.
The largest 10 holders included
FMR LLC, BlackRock, Inc., VANGUARD GROUP INC, Redmile Group, LLC, BAKER BROS. ADVISORS LP, WELLINGTON MANAGEMENT GROUP LLP, PRICE T ROWE ASSOCIATES INC /MD/, COMMODORE CAPITAL LP, Deep Track Capital, LP, and STATE STREET CORP.
This page lists
173
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2024 vs Q3 2024 Across Filers
Q3 2024 holders
170
Q4 2024 holders
173
Holder diff
3
| Investor | Q3 2024 Shares | Q4 2024 Shares | Share Diff | Share Chg % | Q3 2024 Value $ | Q4 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.